WebOct 31, 2024 · WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has … WebApr 11, 2024 · Dyne Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $15.63 on …

Dyne Therapeutics Announces Submission of IND Application to …

WebApr 11, 2024 · Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as … WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. boat hire henley

Dyne Therapeutics Announces FDA Clearance of IND Application …

WebApr 11, 2024 · Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven … WebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven … Web19 hours ago · Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now 12/09/22-8:55AM EST Zacks. Other News for DYN Dyne Therapeutics … cliff\u0027s taphouse